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Abstract: Paliperidone (9-hydroxy-risperidone), the active metabolite of risperidone, was 
approved for treating schizophrenia worldwide in 2006 as paliperidone extended-release (PER), 
and became the first second-generation antipsychotic specifically licensed for treating schizoaf-
fective disorder in 2009. However, at the same time, its comparatively high cost gave rise to 
concerns about the cost-effectiveness of PER as compared with its precursor, risperidone. This 
paper reviews the existing knowledge of the pharmacology, kinetics, efficacy, tolerability, and 
fields of application of PER, and compares PER with risperidone in order to determine whether 
it has a place in antipsychotic therapy. An independent assessment of all relevant publications 
on PER published until July 2010 was undertaken. PER has a unique pharmacological profile, 
including single dosing, predominantly renal excretion, low drug–drug interaction risk, and 
differs from risperidone in terms of mode of action and pharmacokinetics. High-level evidence 
suggests that PER is efficacious and safe in schizophrenia, schizoaffective disorder, and acute 
manic episodes. There is a striking lack of published head-to-head comparisons between PER 
and risperidone, irrespective of indication. Low-level evidence shows a lower risk for hyperpro-
lactinemia and higher patient satisfaction with PER than with risperidone. PER adds to the still 
limited arsenal of second-generation antipsychotics. In the absence of direct comparisons with 
risperidone, it remains difficult to come to a final verdict on the potential additional therapeutic 
benefits of PER which would justify its substantially higher costs as compared with risperidone. 
However, in terms of pharmacology, the available evidence cautiously suggests a place for PER 
in modern antipsychotic therapy.
Keywords: antipsychotic treatment, paliperidone, extended-release, second-generation 
  antipsychotics, psychopharmacology, schizophrenia, bipolar disorder
Background
Paliperidone is the active metabolite of the widely used second-generation antipsy-
chotic, risperidone, is the generic name for 9-hydroxy-risperidone. On December 20, 
2006, palperidone was approved for the acute and maintenance treatment of schizo-
phrenia by the US Food and Drug Administration, and thereafter in many countries 
worldwide. It is marketed as a special slow-release formulation referred to as pali-
peridone extended-release (PER).
In addition, on July 31, 2009, PER became the first second-generation antipsychotic 
licensed for the acute treatment of schizoaffective disorder in the US, either as mono-
therapy or as an adjunct to mood stabilizers and/or antidepressants. At present, PER is 
about to be licensed by the European Medicines Agency for this indication (more spe-
cifically, for the treatment of psychotic and manic symptoms in schizoaffective   disorder, Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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but not for depressive symptoms). A positive   opinion was 
published by the Committee for Medicinal Products for 
Human Use on September 27, 2010 (www.ema.europa.eu). 
Despite several studies on its use in bipolar disorder, PER 
has not yet been licensed for treating any affective disorder. 
This is in contrast with its mother substance, risperidone, and 
many competitors (eg, olanzapine, quetiapine, aripiprazole, 
and ziprasidone). The indications for PER have increased 
from schizophrenia alone to include the wider spectrum of 
affective disorders, a pattern which is also found with the 
other second-generation antipsychotics.
However, the development of increasing indications for 
PER is in contrast with doubts about its cost-effectiveness, 
especially in relation to risperidone, and has given rise to 
cost-effectiveness studies in Europe (Greece, Italy) and in 
the US. Risperidone, first launched in 1991, is available at 
a much lower cost and, in terms of chemistry, differs from 
paliperidone only by a single hydroxyl group. In view of 
the ongoing debate about drugs that are only marginally 
different from their mother substances (“me-too” drugs) and 
the growing interest in the pharmacoeconomics of antipsy-
chotic treatment, Citrome predicted in 2007 that “… with 
the impending availability of oral risperidone as a generic 
medication, the cost of oral paliperidone will likely become 
a significant obstacle to its use”.1
In Germany, for example, after changes were made to the 
funding of the public health system in 2006, PER became the 
first, and thus far only, second-generation antipsychotic for 
which only a small fixed amount of the price is subsidized by 
statutory health insurance funds. Because the manufacturer 
did not reduce the price, patients now have to pay most of the 
cost themselves, which is in contrast with other   antipsychotics. 
As a consequence, PER has become disestablished for all 
practical purposes in Germany for the time being, despite no 
changes to its licensing or approval status.
Accordingly, we set out to gather and evaluate published 
data on the pharmacology, efficacy, and safety, as well as 
the subjective quality of life measures, associated with the 
use of PER. We aimed at assessing all the available evidence 
to answer the question of whether PER and its precursor, 
risperidone, are equivalent, thus determining whether there 
is a place for PER in antipsychotic therapy or not. Special 
attention was paid to characteristics that may distinguish PER 
from other antipsychotics, especially risperidone.
At the time of writing, we could identify 10 review 
articles focusing on PER1–10 with a MEDLINE search using 
PubMed, mainly dealing with efficacy and safety issues. 
There were nine nonsystematic reviews and one   systematic 
review.2 Declarations of interest were missing in two cases.3,8 
For the other eight publications, the authors had direct 
affiliations with Janssen-Cilag or Johnson & Johnson (in 
particular, authors received honoraria from Janssen-Cilag 
and conducted clinical research with the support of Janssen-
Cilag,1 authors were employed by Johnson & Johnson,4 
one author was on the speakers’ bureau for Janssen,5 the 
authors had received honoraria for lectures supported by 
Janssen-Cilag and received fees for advisory board and 
congress presentations,6 one author had been a consultant 
for Janssen-Cilag,2 one author has received research grants 
and speakers’ honoraria from Janssen-Cilag,7 one author 
was employed within Janssen-Cilag, was a member of the 
speakers’ bureau for Janssen-Cilag, and an advisor/consultant 
for Janssen-Cilag, with editorial support and funding from 
Ortho-McNeil Janssen Scientific Affairs,9 and during the 
peer review process the manufacturer of PER was offered 
an opportunity to comment on the article10). The authors of 
the present review, in contrast, do not have any conflicts of 
interest and are not affiliated with the manufacturer of PER 
or risperidone.
On July 21, 2010, we conducted a PubMed search using 
the search term “paliperidone” and retrieved 282 hits. In 
addition, we visited the www.clinicaltrials.com website to 
identify any further ongoing clinical trials involving PER. 
We also visited the US Food and Drug Administration data-
base to obtain data regarding newly reported side effects, 
eg, concerning the potential of PER for abuse and physi-
cal dependence. All retrieved publications were assessed 
independently by two of the authors (MG, MK) for their 
relevance to our research questions. For this review, we 
only considered papers published in peer-reviewed journals. 
Accordingly, 64 papers were selected and the relevant infor-
mation was extracted. Notably, almost all of the published 
papers that presented original data originated from only 
11 clinical studies.
In this paper, we briefly review current issues in the 
antipsychotic treatment of both the schizophrenia spectrum 
and the affective disorders. This includes comparisons of 
efficacy and tolerability of the first-generation and second-
generation antipsychotics, and discussion of the emerging 
clinical problems associated with antipsychotic therapy, 
including adherence to therapy and the metabolic risks 
associated with some antipsychotics. We then summarize 
all available data on PER and assess its place amongst the 
second-generation antipsychotics.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Current issues in treating 
schizophrenia and bipolar disorder
According to the World Health Organization (WHO), severe 
and enduring mental illnesses, such as depression, schizo-
phrenia, and bipolar affective disorder, are major causes of 
disability worldwide.11 In fact, all three rank amongst the 
top 10 on the WHO list of illnesses that cause disability. 
Schizophrenia, bipolar affective disorder, and, to a lesser 
degree, depression, are treated with antipsychotic medication. 
However, despite significant progress in pharmacotherapy 
with antipsychotics, many problems remain unresolved.
A significant problem with antipsychotics is their side 
effect profile. First-generation antipsychotics, such as halo-
peridol or perphenazine, have traditionally been associated 
with extrapyramidal side effects (including irreversible tar-
dive dyskinesia), hyperprolactinemia and its consequences, 
sedation, and vegetative as well as orthostatic symptoms 
to various degrees. Since 1991, with the development of 
risperidone, the so-called second-generation antipsychotics 
have been marketed as being more effective, having fewer 
side effects, and as being potentially neuroprotective, lead-
ing to calls for their early use in patients with   schizophrenia. 
In reality, they have different but equally significant side 
effects, including metabolic syndrome, weight gain, and QTc 
prolongation, depending on the single substance involved. 
This limits their use to a similar degree, just as the side 
effects of the first-generation antipsychotics limit their use. 
  Furthermore, our aging population increases the need to con-
sider cardiovascular problems that may arise as side effects 
of these medications. A systematic review has also shown 
that it remains unclear whether antipsychotics increase or 
reduce cell stress, and claims of neuroprotective properties 
of antipsychotics seem premature.12 Furthermore, there is 
the issue of tardive dyskinesia, which has caused significant 
problems for psychiatric patients in the past. Whilst this is 
much more likely to occur with first-generation antipsychot-
ics, it can also occur with the second-generation agents.
After almost a decade of international opinion that 
advocated the first-line use and superior efficacy of second-
generation antipsychotics, the US Clinical Antipsychotic 
Trials of Intervention Effectiveness study, with its innovative 
endpoint, “time to discontinuation for any cause”, was the first 
to indicate that the second-generation antipsychotics as a group 
are not superior to the older drug, perphenazine.13 Olanzapine 
was shown to be superior to the other tested second-generation 
antipsychotics in terms of time to discontinuation, but was more 
prone than its competitors to cause metabolic side effects.
In the UK, CUTLASS1 (Cost Utility of the Latest 
Antipsychotic Drugs in Schizophrenia Study) found that 
first-generation antipsychotics (largely sulpiride) and 
second-generation antipsychotics (olanzapine, risperidone, 
amisulpride, quetiapine) did not differ in overall efficacy 
as measured by the Positive and Negative Syndrome Scale 
(PANSS), extrapyramidal side effects, quality of life, and 
even patient preference over a period of 52 weeks.14 A nonsig-
nificant trend of lower direct and indirect costs was reported 
in the first-generation antipsychotic arm.
An influential meta-analysis by Leucht et al15 compared 
nine second-generation antipsychotics (including risperi-
done but not paliperidone) with a number of first-generation 
antipsychotics (mainly haloperidol) in terms of efficacy and 
  tolerability. With regard to efficacy, the authors found only 
four second-generation antipsychotics (clozapine, olanzapine, 
amisulpride, risperidone) to be superior to first-generation 
antipsychotics in overall efficacy, whilst others, such as arip-
iprazole, quetiapine, and ziprasidone, were not.15 A similar 
pattern was also seen in the treatment of negative symptoms. 
This supports the idea that second-generation antipsychotics 
are not a homogenous group, and cannot be defined by their 
specific effects on negative symptoms or any other specific 
features. In terms of tolerability, Leucht et al showed that 
all second-generation antipsychotics caused significantly 
fewer extrapyramidal side effects than did haloperidol, but 
this effect diminished when they were compared with low-
potency first-generation antipsychotics. These investigators 
also showed that all the second-generation antipsychotics, 
with the exception of ziprasidone and aripiprazole, caused 
more weight gain than haloperidol, to varying degrees, but 
not more than is seen with the low-potency first-generation 
antipsychotics. A similar risk pattern of metabolic side effects 
with the second-generation antipsychotics was reported by 
a follow-up study from the same research group.15 In terms 
of extrapyramidal side effects, it seems that the superiority 
of second-generation antipsychotics in this regard reduces 
significantly when low-potency first-generation antipsychot-
ics with a low incidence of extrapyramidal symptoms are 
used, and when their dosing is appropriately low. However, 
there is no doubt that, by and large, second-generation 
antipsychotics as a group produce less tardive dyskinesia, 
although the difference appears less pronounced than pre-
viously thought.16 Lepping et al showed improvements of 
limited clinical relevance for all antipsychotics, with the 
exception of amisulpride and olanzapine, which appeared 
most clinically relevant, being the only antipsychotics that Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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achieved Clinical Global Impression-Severity (CGI-C) score 
improvements in the moderate range. In keeping with other 
meta-analyses, their results showed that aripiprazole, que-
tiapine, sertindole, and ziprasidone showed smaller CGI-C 
score improvements than haloperidol (using PANSS and/
or Brief Psychiatric Rating Scale [BPRS] score translation 
into CGI-C scores).17
Important obstacles in the effective treatment of schizo-
phrenia include nonadherence, which is at least in part due 
to patients’ lack of insight. This has increased the necessity 
for drugs that can be taken once daily, ie, those having a 
long elimination half-life. Depot antipsychotics are the most 
common way of improving adherence to treatment, even 
in first-episode schizophrenia.18 However, Hamann et al 
recently found that most psychiatrists have to judge depot 
medication as superior with respect to relapse prevention 
before they recommend it to patients.19 This clearly leaves 
room for more long-acting oral antipsychotic compounds.
Polypharmacy is commonplace in the treatment of psy-
chiatric patients.20 Whilst this is partially due to the many 
comorbidities that patients with schizophrenia suffer from, 
and may even be beneficial in some cases,21 polypharmacy 
highlights the need for psychotropic medication to be as 
little prone to drug–drug interactions as possible, especially 
in aging and multimorbid populations.
In summary, there is an increasing understanding that 
second-generation antipsychotics are diverse and should 
not be seen as a homogenous group. Their efficacy, as 
well as their side effect profile, is variable. In relation to 
first-generation antipsychotics, each second-generation 
antipsychotic needs to be seen on its own merits. A number 
of credible studies and meta-analyses have suggested that 
clozapine is the most efficacious antipsychotic, followed by a 
group consisting of amisulpride, olanzapine, and risperidone, 
and that these four agents are more effective than the various 
first-generation and other second-generation antipsychotics. 
The second-generation antipsychotics have very different 
risks of sedation, weight gain, hyperprolactinemia, QTc 
prolongation, and extrapyramidal side effects. The desirable 
attributes for any antipsychotic are ease to administration, 
a long half-life with few drug interactions, minimal side 
effects and improved adherence, and availability at a cost 
that is justifiable in the context of increasingly reduced health 
care resources.   Notably, PER, in contrast with risperidone, 
was not part of any of these seminal studies on the use of 
antipsychotics.
Antipsychotics have also increasingly been used in the 
treatment of bipolar affective disorder, where it is being 
  suggested that antipsychotics may be useful as mood 
  stabilizers in the treatment of acute mania as well as in 
maintenance therapy. However, most studies have been short, 
and their results need to be replicated in larger studies with 
varying outcome measures, to avoid the misinterpretations 
that occurred with the schizophrenia studies involving the 
second-generation antipsychotics. Very recently, quetiap-
ine became the first second-generation antipsychotic to be 
licensed as an add-on in treating depression. Altogether, 
second-generation antipsychotics are increasingly expanding 
their scope and licensed indications from schizophrenia into 
the affective disorder spectrum.
Pharmacological properties
Pharmacodynamics
A monoaminergic antagonist belonging to the chemi-
cal class of benzoxisoxazole derivatives, paliperidone 
is a centrally acting dopamine D2- and serotonin 5-HT2A 
receptor antagonist with predominantly 5HT2A antagonist 
activity.22   Additionally, it is an antagonist at alpha1- and 
alpha2-adrenergic receptors and H1-histaminergic receptors, 
which may explain weight gain, orthostatic hypotension, 
and sedative side effects. Paliperidone has no affinity with 
cholinergic muscarinic receptors, predicting a low risk of 
anticholinergic side effects, including cognitive dysfunc-
tion and constipation, and also has no significant action at 
beta1- and beta2-adrenergic   receptors.22 Like risperidone, 
its mother substance, paliperidone is a potent dopamine D2 
antagonist. The Ki values for binding to D2 versus 5-HT2A 
receptors for risperidone and paliperidone are 5.9 and 
4.8 nM versus 0.16 and 0.25 nM, respectively.23 The off-rate 
for dissociation from human cloned D2 receptors in tissue 
culture cells is faster for paliperidone (60 seconds) than 
for risperidone (27 minutes).23 Karlsson et al investigated 
the receptor occupancy of a single dose of two different 
formulations of paliperidone, an intermediate-release for-
mulation of paliperidone 1 mg, and an extended-release 
formulation (PER 6 mg) in three and four healthy subjects, 
  respectively.22 With positron emission tomography measure-
ments, D2 and 5HT2A receptor occupancy was calculated with 
two radioligands before administering paliperidone and at 
around the time of the predicted peak plasma concentration. 
Whereas a single dose of paliperidone intermediate-release 
corresponded to a median D2 receptor occupancy of 48% at 
2.5 hours postdose and a median 5HT2A receptor occupancy 
of 65% at 4.5 hours postdose, a single dose of PER 6 mg 
corresponded to a median D2 receptor occupancy of 64% 
at 22 hours postdose (peak plasma concentration), and this Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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decreased to a median of 53% at 46 hours postdose. These 
findings suggest that the estimated effective dose of PER 
(.60% D2 receptor occupancy) is more than 3 mg per day. 
Brain imaging studies have consistently predicted that PER 
6–9 mg daily induces striatal D2 receptor occupancy rates 
of 70%–80%,24 and suggest therapeutic efficacy of antip-
sychotic drugs when a D2-receptor occupancy greater than 
65% is reached in the basal ganglia,25 whereas an increased 
incidence of extrapyramidal symptoms occurs when occu-
pancy exceeds 80%–85%.25 Due to looser binding to D2 
receptors and lower fluctuations of levels in plasma,26 PER is 
theoretically associated with a lower risk of extrapyramidal 
side effects than risperidone.23 Therefore, PER can be seen 
as having different pharmacodynamic properties and a dif-
ferent neural mechanism of action to risperidone.
Pharmacokinetics
Paliperidone has been introduced and approved worldwide 
in a formulation that uses the so-called osmotically controlled 
release oral delivery system (OROS©, ALZA Corporation, 
Mountain View, CA). Paliperidone itself and paliperidone 
intermediate-release have been tested, but have not been 
approved. The OROS technology has been studied and 
refined over the past 30 years. It has been used for a number 
of commonly used medications, including nifedipine, vera-
pamil, doxazosin, oxybutynin, and methylphenidate.27 The 
system allows for continuous delivery of the pharmacologi-
cally active drug over a 24-hour period,27,28 and consists of 
an osmotically active trilayer, containing two drug layers 
and a push compartment, surrounded by a semipermeable 
membrane. After ingestion, the overcoat erodes in the gas-
trointestinal tract and water passes through the semiperme-
able membrane. The water interacts with the hydrophilic 
polymers of the core which, in turn, swells and forms a gel, 
thereby pushing paliperidone outwards through a delivery 
orifice. Because the passage of water through the membrane 
is at a fixed rate, it controls the rate of drug release from the 
system into the lumen of the intestinal tract.27,29 The OROS 
principle avoids peak-to-trough variations in plasma 
concentrations,6,27 with only minimal fluctuations in plasma 
drug levels.28 After a single 12 mg dose of PER, the 
peak-to-trough fluctuation is only 38%, which is in contrast 
with a fluctuation of 125% seen after a single 4 mg dose of 
risperidone.30 In the dosage range of 3–15 mg once daily, the 
overall pharmacokinetic profile of PER is dose-dependent.28,31 
Maximum plasma concentrations are reached 24 hours after 
administering a single oral dose, and steady-state plasma 
levels are achieved after four daily doses.28 The absolute 
bioavailability of PER is approximately 28%.32 According to 
the manufacturer’s product information, a single dose of PER 
12 mg administered with food is associated with a 60% 
increase in the maximum plasma concentration and a 54% 
increase in the area under the plasma concentration-time 
curve compared with administration in the fasting state in 
ambulatory individuals. However, the underlying mecha-
nisms are unclear, because PER was administered without 
regard to food intake in clinical trials.33,34 Despite that, it has 
been suggested that PER may be administered without regard 
to meals.33,34 Finally, the tablet has to be swallowed whole 
and must not be chewed, split, or crushed.34 When administer-
ing the drug, patients should be informed by the treating 
physician that the shell of the tablet is nonabsorbable and 
thus will be excreted in their feces. This is particularly impor-
tant in patients suffering from paranoid or psychotic symp-
toms who might interpret the excretion of a foreign object 
in a delusional manner.
As already mentioned, paliperidone is the active metabo-
lite of risperidone, and is thus generated after oral admin-
istration of risperidone by CYD2D6-related hydroxylation 
of risperidone. Paliperidone is minimally metabolized in 
the liver by the cytochrome P450 (CYP) enzyme system 
and, therefore, has a low potential for causing drug–drug 
interactions.35 The only two CYP isoenzymes identified 
to break down paliperidone to some extent are CYP 3A4 
and 2D6.34
Although there are no human data regarding the influ-
ence of PER on P glycoprotein, a study by Zhu et al36 
demonstrated that risperidone and, to a lesser extent, pali-
peridone intermediate-release, have the potential to inhibit P 
  glycoprotein-mediated transport. Thus, the pharmacokinetics, 
and hence the pharmacodynamics, of coadministered drugs 
can be influenced via this mechanism. Studies in healthy sub-
jects have revealed no clinically relevant effects of paroxetine 
on the pharmacokinetics of PER.37 Population pharmacoki-
netic analyses also suggest that paliperidone exposure and 
clearance do not differ between extensive or poor metabo-
lizers of CYP 2D6 substrates.33 Four primary metabolic 
pathways (each accounting for #10% of the oral dose) were 
identified, ie, dealkylation, hydroxylation, dehydrogenation, 
and benzisoxazole scission.34,38 Although hepatic metabolism 
is present to some degree, renal excretion seems to be the pri-
mary route of elimination for paliperidone, with 59% of the 
oral dose excreted unchanged in the urine.38 About half of the 
renal excretion occurs by active secretion.38 In spite of hepatic 
metabolism, the impact of moderate hepatic impairment on 
paliperidone pharmacokinetics is not considered clinically Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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relevant, so dosage adjustments in patients with mild to 
moderate hepatic impairment are not required.34,39 The impact 
of renal impairment on plasma and urine pharmacokinetics 
of orally administered PER 3 mg was assessed in subjects 
with varying degrees of renal impairment versus subjects 
with normal renal function.40 The total paliperidone clearance 
decreased with increasing degrees of renal impairment, and 
was approximately 71% lower in subjects with severe renal 
impairment compared with healthy subjects. According to 
the manufacturer’s prescribing information for patients with 
mild renal impairment (creatinine clearance 50–80 mL/min), 
the maximum recommended dose is 6 mg/day, whereas for 
patients with moderate-to-severe renal impairment (creati-
nine clearance 10–50 mL/min), the maximum recommended 
dose is 3 mg/day.34 An open-label, two-period, randomized, 
crossover study in 30 healthy males found that trimethoprim, 
a potent organic cation transport inhibitor, did not influence 
the pharmacokinetics of PER, which is an organic cation 
at physiological pH.41 Therefore, no clinically important 
drug interactions are expected when PER is administered 
with organic cation transport inhibitors.41 Furthermore, the 
pharmacokinetics of PER are not significantly affected by 
age.42 During the absorption phase after a single dose, PER 
concentrations are similar between elderly and young adults. 
No dose adjustment of PER is required in elderly patients, 
unless they have renal impairment. Paliperidone is a racemic 
mixture of (+)- and (-)- enantiomers. In vitro, there is no 
qualitative or quantitative difference in the pharmacological 
activities of these enantiomers.33,43 In summary, PER differs 
from risperidone in terms of two important pharmacokinetic 
properties, ie, a low extent of enzymatic metabolism and 
reduced plasma level fluctuations.
Efficacy studies
Based on the data of three pivotal clinical studies that 
investigated the efficacy of PER in patients with schizo-
phrenia, pooled analyses have been done to investigate 
its efficacy in acute-phase and long-term treatment, in 
recently diagnosed schizophrenia, for negative symptoms 
of schizophrenia, for prominent affective symptoms in 
schizophrenia, and in patients previously treated with 
risperidone.
More recent clinical studies have been conducted 
to evaluate the efficacy of PER in elderly patients, and 
for prevention of symptom recurrence, schizophrenia-
related insomnia, schizoaffective disorder, acute mania, 
and mixed episodes of bipolar I disorder. Finally, there is 
only one   clinical head-to-head study that compared PER 
with   quetiapine. Table 1   summarizes the findings of these 
studies.
Patients with schizophrenia
Until the search date for the present review, there were three 
published studies that examined the efficacy of PER.44–46 
These studies had a six-week, double-blind, randomized, 
fixed-dose, placebo-controlled or active-controlled (olan-
zapine 10 mg per day), and parallel-group design. The mean 
total change in the PANSS47,48 was the primary outcome 
measure. The PANSS is a 30-item, widely used, validated 
scale quantifying key clinical features of schizophrenia 
in five domains (positive symptoms, negative symptoms, 
disorganized thought, uncontrolled hostility/excitement, 
and anxiety/depression). The scale scoring for each item 
ranges from 1 (absence of symptoms) to 7 (most severe 
symptoms).   Generally, a score of 70–120 equates to the 
moderate-to-severe illness range. PANSS is a useful tool, 
in that a 20%–30% change in the total PANSS from base-
line represents a clinically meaningful improvement in 
overall illness severity. PANSS factor scores,48 response 
rates (patients with $30% reduction in PANSS total score 
at endpoint), CGI-Severity (CGI-S) scores49 and Personal 
and Social Performance (PSP)50,51 scores were the second-
ary outcome measures. The latter scale measures personal 
and social functioning on a 100-point scale in 10-point 
increments (ie, scores of 1–10 represent lack of autonomy 
in basic functioning, and scores of 91–100 represent excel-
lent functioning). It accounts for four domains of behavior, 
ie, socially useful activities, relationships, self care, and 
disturbing and/or aggressive behavior. A clinically mean-
ingful change is reflected by improvement in one category 
(ie, 10 points).51
All three studies had the same design, starting with   
a one-week screening phase followed by a six-week double-
blind phase (with fixed doses of PER, olanzapine 10 mg/day, 
or placebo). Emsley et al52 conducted a continuation study 
in patients who had either completed one of the six-week, 
double-blind studies or had terminated more than 21 days into 
the study because of lack of efficacy with a 52-week, open-
label, extension phase (with flexible doses of PER resulting 
in classification of three treatment groups with regard to the 
sequence of administered agents, ie, placebo/PER, PER/PER, 
and olanzapine/PER).
In the first study, Marder et al randomized 444 subjects 
with chronic schizophrenia and current acute exacerbation 
(PANSS score range 70–120; mean ± standard deviation 
[SD] baseline score 94 ± 12) to three treatment arms, ie, PER Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Table 1 Paliperidone efficacy studies
Study Methods Results
Efficacy in schizophrenia
Kane et al45 n = 628
6 weeks, multicenter, randomized, DB
Placebo-controlled active-controlled
Dosage 6, 9, and 12 mg
Active control, olanzapine 10 mg
Any dosage was effective
Significant improvement PANSS
Significant improvement PANSS Marder factor scores
Significant improvement PSP
Marder et al46 n = 444
6 weeks, multicenter, randomized, DB,
Placebo-controlled active-controlled
Dosage 6 and 12 mg
Active control olanzapine 10 mg
Significant improvement PANSS
Significant improvement PSP: 6 mg
Davidson et al44 n = 618 
Dosage 3, 9, 15 mg 
Active control olanzapine 10 mg
Any dosage was effective  
Significant improvement in PANSS  
Significant improvement in PSP
Special about this study: rapid onset of action
Significant improvement on day 4
Efficacy in prevention of symptom recurrence in patients with schizophrenia
Kramer et al61 n = 628  
6 weeks, multicenter, randomized, DB  
Dosage 3, 6, 9, 12, 15 mg
Symptom recession within 6 weeks: 25% with PeR, 
53% with placebo.  
Special about this study: Efficacy was measured  
by rate of symptom recurrence under stable 
medication with PeR
5 phases
8 weeks running: minimum 2 weeks, discharge  
6 weeks
Fixed dose, DB
Efficacy in schizophrenia compared with quetiapine
Canuso et al64 6 weeks, DB, randomized, placebo-controlled. Significant improvement PANSS after 2 weeks:  
only with PeR
2 weeks monotherapy, 4 weeks add-on therapy Significant improvement PANSS after 6 weeks  
with PeR,
Significantly greater improvement compared  
with quetiapine
Efficacy in elderly patients with schizophrenia
Tzimos et al59 n = 114, Significant improvement PANSS
Randomized, flexible dosing, placebo-controlled
6 weeks, DB, 24 weeks, open-label,
mean modal dose 8.3 mg/day
Efficacy in schizophrenia-related insomnia
Luthringer et al62 n = 42 
3 weeks, randomized, DB, placebo-controlled 
fixed dose 9 mg
Significant improvement in sleep latency, sleep onset 
latency, number of awakenings, time awake in bed, 
stage 11 sleep duration, total sleep duration,  
sleep period time, Stage 2 sleep duration,  
ReM sleep duration
Efficacy in schizoaffective disorder
Canuso et al57 n = 316 Significant improvement PANSS at 12 mg
6 weeks, randomized, DB, multicenter, Significant improvement YMRS/HAM-D
placebo-controlled
dose (flexible): 6–12 mg
Efficacy in bipolar disorder (manic episode)
Berwaerts et al66 n = 469 Significant improvement YMRS at 12 mg only
3 weeks, randomized, DB, placebo-controlled.
fixed dose: 3, 6, 12 mg
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6 mg or 12 mg fixed doses, placebo, and olanzapine 10 mg 
per day.46 Of the 444 patients screened and randomized, 
432 patients were included in the intention-to-treat group. 
  Demographic and baseline characteristics of the 432 inten-
tion-to-treat patients were similar across all groups. Only 
192 patients (43%) of the 444 patients randomized com-
pleted the study. The olanzapine arm was an active control 
group to confirm assay sensitivity and was not included in 
the statistical models for efficacy analyses, thus missing the 
opportunity for a useful head-to-head analysis. With both 
doses of PER, there was a statistically significant difference 
in PANSS total score in comparison with placebo (6 mg dose, 
P = 0.006; 12 mg dose, P , 0.001). In the 6 mg group, there 
was also a statistically significant difference from placebo at 
every postbaseline rating from day 4 onwards (P , 0.05), 
and in the 12 mg group from day 15 onwards (P , 0.05). 
Clinical response rates (defined by $30% improvement from 
the baseline PANSS total score) were also statistically sig-
nificantly higher in the PER groups than in the placebo group 
(6 mg 50% [P , 0.03]; 12 mg 51% [P = 0.012]; placebo 
34%). Olanzapine 10 mg per day yielded a response rate of 
46%. The rate of patients classified as “marked/severely ill/
extremely severe” on the CGI-S scale decreased in both the 
PER arms and in the active control group when comparing 
baseline and the most recent observation. This decrease was 
more pronounced than in the placebo arm (6 mg PER 57.6% 
to 26.1%; 12 mg PER 64.0% to 20.7%; placebo 60% to 
44.7%; olanzapine 70.5% to 29.6%). PSP scores improved 
in both PER dose groups, but only the 6 mg dose group 
achieved a statistically significant change in comparison 
with the placebo group (P = 0.007).
Kane et al performed a similar prospective, random-
ized, placebo-controlled study45 that used three PER doses 
instead of only two, ie, 6, 9, and 12 mg daily. Six hundred 
and thirty patients were recruited, and 415 (66%) completed 
the study. Demographic and baseline characteristics were 
matched across the five treatment arms. All three doses of 
PER achieved a significantly stronger decrease in mean 
PANSS total score (P , 0.001) and in all five Marder 
factor scores from baseline to endpoint (P , 0.001). For 
PER 12 mg, the mean total PANSS score changes were 
significantly greater than with placebo starting from day 
4 (P , 0.01), and for the 6 mg and 9 mg doses from day 
8 onwards (P , 0.05). Response rates ($30% decrease in 
PANSS total score) were nearly doubled in the PER groups 
(6 mg, 56%; 9 mg, 51%; 12 mg, 61%) as compared with 
placebo (30%, P , 0.001), while the response rate with 
the active control, olanzapine 10 mg per day, was similar 
(52%). A strikingly lower percentage of subjects in the 
PER group was classified as “marked/severely ill/extremely 
severe” on CGI-S score from baseline to endpoint (6 mg 
PER, 63% to 21%; 9 mg PER, 57% to 23%; 12 mg PER, 
64% to 16%) in comparison with the placebo (60% to 
51%). In the olanzapine 10 mg/day group, the correspond-
ing values were 64% at baseline and 24% at endpoint. 
PSP scale scores improved statistically significantly from 
baseline to endpoint for all three doses of PER compared 
with placebo (P , 0.001).
Using a similar study design, Davidson et al44 adminis-
tered a broader dosage range of PER, ie, 3 mg, 9 mg, and 
15 mg. Six hundred and eighteen patients were randomized, 
and 365 (59%) completed the study. Demographic and base-
Table 1 (Continued)
Study Methods Results
Efficacy in bipolar disorder (manic and mixed episode)
vieta et al68 n = 493 
Placebo-controlled, active-controlled, 
fixed dose, 3, 6, 9, 12 mg, 
Active control: quetiapine 400–800 mg 
followed by 9 weeks, multicenter, randomized,  
DB, placebo-controlled
dosages 3, 6, 9, 12 mg 
Active control: quetiapine 400–800 mg
Significant improvement YMRS, no significant 
difference between quetiapine and PeR in 
treatment effect, response rate,  
remission rate
Long-term efficacy of PER in treatment of acute schizophrenia
emsley et al52 n = 1083 
52 weeks, open-label extension of the three  
pivotal six-week studies
flexible dose: 3–15 mg
Maintenance of improvements of PANSS, PSP and 
CGi-S of the three six-week double-blind studies
PeR can maintain improvements in symptoms and 
personal and social functioning.
Abbreviations: PER, paliperidone extended release; n, number of subjects; DB, double-blind; PANSS, positive and negative symptom scale in schizophrenia; PSP, Personal 
and Social Performance scale; YMRS, Young Mania Rating Scale; HAM-D, Hamilton Depression Score; CGI-S, Clinical Global Impression-Scale.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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line characteristics were similar across the treatment groups. 
All PER doses achieved significantly greater improvements 
in PANSS total and Marder factor scores at endpoint versus 
placebo (P , 0.01). From day 4, all three PER doses showed 
statistically significantly greater PANSS score reductions 
than the placebo. With all three PER doses, the clinical 
response at endpoint was more than twice as high as for the 
placebo (3 mg, 40%; 9 mg, 46%; 15 mg, 53%; placebo, 18%, 
P = 0.005). In comparison, the proportion of responders in 
the olanzapine 10 mg/day group was 52% at endpoint. PSP 
scale scores from baseline to endpoint were also statistically 
significantly improved with all three doses of PER versus 
the placebo (3 mg, 8.3 ± 17.1; 9 mg, 7.6 ± 14.2; 15 mg, 
12.2 ± 15.7; placebo, -1.5 ± 15.8, P , 0.001). Finally, 
markedly fewer patients in the PER groups were classified as 
“marked/severely ill/extremely severe” at endpoint compared 
with baseline on the CGI-S scale versus the placebo group 
(score reductions: 3 mg, 54% to 32%; 9 mg, 52% to 23%; 
15 mg, 57% to 17%; placebo, 56% to 49%).
Post hoc analyses of the pivotal  
PeR studies
Efficacy in acute-phase treatment
Meltzer et al53 analyzed the pooled data of the six-week, 
double-blind phases of the three aforementioned pivotal 
studies44–46 to investigate the efficacy, safety, and toler-
ability of PER for acute-phase treatment of schizophrenia. 
Overall, the findings indicated clinical efficacy for all the 
administered doses of PER (3, 6, 9, 12, and 15 mg) with 
regard to changes in PANSS total, PANSS subscale factor, 
and PSP (P # 0.001), while the 3 mg dose was least effective. 
Additionally, a statistically significantly greater proportion 
of PER-treated patients achieved a clinical response at all 
doses (defined in two ways, ie, a $30% decrease in PANSS 
total scores from baseline to endpoint or   improvement of 
at least one 10-point PSP category) compared with placebo 
(P # 0.001). Thus, PER 6 mg/day was judged as the   lowest 
effective dose for the treatment of patients with acute 
schizophrenia.
Long-term efficacy
Optimal control of psychotic symptoms in patients experienc-
ing an acute exacerbation is one of the primary goals of dis-
ease management in patients with schizophrenia. To address 
this issue, the participants in the three international, multi-
center, double-blind, and the placebo-controlled open-label 
six-week studies of PER44–46 were again enrolled into a 
52-week open-label extension phase in which all patients 
received flexibly dosed PER (3, 6, 9, 12, and 15 mg/day), 
with a starting dose of 9 mg/day.52 The primary objective of 
that study was to assess the long-term efficacy, safety, and 
tolerability of PER 3–15 mg/day. Of 1083 patients enrolled, 
507 (47%) completed the 52-week, open-label extension 
phase. Outcome measures included PANSS, PSP, and CGI-S. 
  During the open-label extension phase, the improvements in 
all efficacy measures (PANSS total score, PANSS positive 
and negative Marder factor,48 PSP, and CGI-S) were main-
tained in the active treatment groups in the six-week, double-
blind phase. Although PANSS total score improved from the 
open-label extension phase baseline in all groups, the most 
marked reduction was in the placebo/PER group, such that 
by 24 weeks of treatment, all groups had a similar PANSS 
total score. The authors concluded that PER can maintain 
improvements in symptoms and functioning.52
Recently diagnosed schizophrenia
In the early course of their illness, schizophrenic patients 
are known to be more responsive to antipsychotic treatment, 
prolonging remission and preventing future episodes. In 
this context, Canuso et al performed a post hoc analysis54 
of the data of the three pivotal trials of PER44–46 and their 
open-label one-year extensions.52,53 The accumulated study 
population was divided into two groups with either recently 
diagnosed schizophrenia (defined as time since diagnosis 
up to three years) or not recently diagnosed schizophrenia 
(defined as time since diagnosis more than three years). 
In the double-blind phase, 259 patients (21.9%) and the 
open-label phase 188 patients (25.3%) were classified as 
recently diagnosed. Both populations improved with PER 
versus placebo on PANSS total score, CGI-S, and PSP at the 
endpoint of the double-blind phase compared with placebo 
(all P , 0.05). Significant improvements in both populations 
were observed at the open-label endpoint (P , 0.0001), with 
greater improvement in the PANSS total score (P , 0.001) 
and PSP (P , 0.001) in the recently diagnosed population. 
The authors concluded that patients with recently diagnosed 
schizophrenia particularly benefit from PER treatment with 
regard to symptom reduction and functional benefit in the 
long term.
effects on negative symptoms of schizophrenia
Negative symptoms of schizophrenia are known to be 
associated with functional disability and poor prognosis. 
Improvement of negative symptoms is an important goal 
of antipsychotic treatment.55 In this context, Turkoz et al56 
investigated the direct and indirect effects of PER on   negative Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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symptoms in a post hoc pooled analysis of the three pivotal 
studies. PER treatment, compared with placebo, was associ-
ated with a significant improvement in negative symptoms, 
representing a 22% reduction from baseline in PANSS 
negative and anxiety/depression factor scores. Path analysis 
indicated that up to 33% of negative symptom improvement 
was a direct treatment effect of PER. Changes in positive 
symptoms and anxiety/depression symptoms mediated 
indirect effects on negative symptoms (51% and 18%, 
respectively). An inverse effect was induced by changes in 
movement disorders (2.1%). All doses of PER resulted in 
statistically significant improvements in negative symptom 
scores at endpoint compared with placebo (P , 0.001). The 
authors concluded that PER has a direct effect on negative 
symptoms, with indirect mediation via changes in positive 
and depressive symptoms.
effects in schizophrenia patients with prominent 
affective symptoms
In 2010, Canuso et al57 performed a post hoc analysis of the 
pooled data of the three six-week, multicenter, double-blind, 
randomized, placebo-controlled, parallel-group Phase II stud-
ies of PER. The aim of this study was to evaluate the effects of 
PER in patients with schizophrenia and prominent affective 
symptoms. Prominent affective symptoms were defined as 
depressive (PANSS depression item score of $5 [moder-
ately severe]) and/or manic (PANSS grandiosity score $4 
[moderate], plus a score of $4 [moderate] on at last one 
PANSS item for excitement, hostility, uncooperativeness, or 
poor impulse control. Among 193 patients with prominent 
affective symptoms identified in the initial population, 140 
(16.3%) received PER and 53 received the placebo. PER 
showed statistically significant mean improvements versus 
the placebo in PANSS total (P , 0.001) and all factor scores 
(P , 0.01). Statistically significant mean improvements 
were observed in PSP (P = 0.004) and CGI-S (P , 0.001) 
scores. The authors concluded that PER was associated with 
statistically significant greater improvements in symptoms, 
functioning, and overall clinical status, as compared with 
the placebo in patients with schizophrenia and prominent 
affective symptoms.
Efficacy in patients previously treated  
with risperidone
Canuso et al58 performed a study based on an analysis of 
the pooled data of the three aforementioned clinical trials 
of PER44–46 to investigate whether patients with persist-
ing active symptoms of schizophrenia when treated with 
  risperidone benefit from switching to PER as compared with 
switching to placebo. Previous treatment with risperidone 
was defined as treatment for at least four weeks within two 
weeks of study entry. Mean previous daily risperidone 
dosage was 4.1 mg in both switch groups, whereas the 
duration of previous risperidone treatment was 418.8 days 
in the PER switch group and 527.0 days in the placebo 
switch group. One hundred and ninety-eight patients met 
the inclusion criteria, and study completion rates were 
61.3% for PER versus 42.9% for placebo. At endpoint, 
PER showed statistically significant improvement versus 
placebo (P , 0.05) in PANSS, CGI-S, and PSP scores. The 
authors considered PER to be significantly more effective 
than placebo in patients who remained symptomatic with 
previous risperidone treatment.
Efficacy in elderly patients with schizophrenia
Tzimos et al conducted a six-week, double-blind, random-
ized, flexible-dose, placebo-controlled trial in 114 patients 
with schizophrenia at least 65 years of age.59 The mean 
age of patients in the study population was 69.7 ± 4.5 
years. The assessment of safety and tolerability of flexible 
doses (3–12 mg/day) of PER compared with placebo was 
the primary aim of this study. Efficacy measures included 
PANSS total47 and Marder factor scores,48 CGI-S scores,49 
PSP scale,50,51 and the Schizophrenia Quality of Life scale.60 
Subjects were randomized 2:1 to PER 6 mg/day or placebo. 
All eligible subjects were hospitalized from the first day of the 
double-blind phase for at least 14 days. After one week, the 
dose of PER was increased to 9 mg/day, provided that 6 mg/
day had been tolerated. In the further course of the study, 
doses were adjusted in 3 mg increments. Dose increases were 
permitted once weekly, whereas decreases could be made 
at any time. Relevant baseline characteristics were similar 
between the two treatment arms. Study completion was 
achieved in 84% of the PER group and 68% of placebo group. 
Mean modal dose of PER was 8.3 ± mg/day. There was a 
double-blind phase of six weeks followed by an open-label 
phase of 24 weeks, during which all patients were treated 
with PER. Because the study was predominantly performed 
to identify the safety and tolerability profile of PER in elderly 
patients, no formal statistical analysis was conducted, so the 
efficacy results must be interpreted with caution. During the 
double-blind phase, the PER group showed significantly 
greater improvement than the placebo group for PANSS fac-
tors of positive symptoms, negative symptoms, and   anxiety/
depression, with a separation between treatment groups 
apparent from day 15 onwards. Similar PANSS scores were Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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achieved by the end of the open-label phase, irrespective of 
the treatment received during the double-blind phase. There 
was no significant difference in the median change detected 
in the CGI-S scores between the treatment groups. Regarding 
results on the PSP or Schizophrenia Quality of Life scale, 
there were no substantial differences between the groups. 
The authors concluded that patients treated with PER who 
continued in the extension phase maintained the improve-
ments they had gained.
Prevention of symptom recurrence in patients  
with schizophrenia
Subsequent to successful antipsychotic treatment of an acute 
exacerbation of schizophrenia, prevention of relapse becomes 
important. Kramer et al performed a randomized, double-
blind, placebo-controlled, parallel-group, long-term study to 
assess the efficacy of PER (flexible dosing of 3–15 mg/day) 
compared with placebo.61 The study design included five 
phases, ie, screening for up to five days, a run-in phase 
with flexible dosing for eight weeks, a stabilization phase 
with a fixed dose for six weeks, a double-blind phase with 
application of PER or placebo for variable duration, and a 
completion phase. The primary outcome measure was time 
to first recurrence in the double-blind phase, whereas recur-
rence was defined according to a set of predefined criteria. 
The secondary outcome measures were the change from 
baseline to endpoint on the PANSS total and CGI-S scores. 
Recurrence occurred in 52% of the subjects on the placebo 
and 25% on PER (P = 0.005). Postrandomization treatment 
with PER maintained the improvement in symptom sever-
ity achieved after the open-label phases, and mean PANSS 
total scores remained stable after an initial slight increase. 
In comparison, worsening was statistically significantly 
greater for patients randomized to placebo (P , 0.001). 
Discontinuation rates in the double-blind phase were higher 
in the PER group (n = 20, 19%) compared with the placebo 
(n = 8, 8%). The authors concluded that PER (flexibly dosed 
at 3–15 mg/day) was superior to the placebo in preventing 
recurrence after stabilization.
Schizophrenia-related insomnia
Luthringer et al62 performed a randomized, double-blind, 
placebo-controlled, three-week study in patients (n = 42) 
with schizophrenia-related insomnia. The primary outcome 
was the effect of PER on sleep architecture. Patients received 
PER 9 mg/day or matching placebo during the 14-day 
double-blind phase. Polysomnograms were used to evaluate 
sleep architecture and sleep continuity during the 14-day 
double-blind phase. The effect of PER on patient-rated 
changes in sleep quality were assessed by daily evaluation 
using the Leeds Sleep Evaluation Questionnaire.63   Thirty-six 
patients (17 on PER and 19 on placebo) completed the study. 
PER treatment versus placebo resulted in clinically and 
statistically significant differences in sleep measurements 
from baseline to endpoint, including a reduction in persisting 
sleep latency, sleep onset latency, number of awakenings 
after sleep onset, time awake in bed, and stage 11 sleep 
duration. Prolongation in total sleep time, sleep period 
time, Stage 2 sleep duration, and rapid eye movement sleep 
duration were also observed. The results suggested that PER 
had a positive effect on sleep architecture, continuity, and 
patient-rated sleep quality, without producing or worsening 
daytime sleepiness.
Efficacy compared with other antipsychotics  
in schizophrenia
At the time of writing, there was only one published peer-
reviewed clinical trial dealing with the clinical efficacy of 
PER compared with other antipsychotics in the treatment of 
schizophrenia. Canuso et al conducted a randomized, double-
blind, placebo-controlled, six-week trial to investigate the 
efficacy of PER versus quetiapine in patients with recently 
exacerbated schizophrenia with two phases,64 ie, a two-week 
monotherapy phase followed by a four-week additive-therapy 
phase during which participants received additional psycho-
tropic medications, including antipsychotics. Patients had 
been experiencing an acute exacerbation for less than four 
weeks, but more than four days. At baseline, patients were 
randomly assigned in a 2:2:1 ratio to treatment with PER, 
quetiapine, or placebo. PER was initiated at 6 mg (days 1–3) 
and increased to 9 mg on day 4, with an optional increase to 
12 mg at day 8. Quetiapine was initiated at 50 mg/day on day 
1, increased on day 2 to 200 mg/day, and with subsequent 
daily escalation up to 600 mg on day 5, and an optional dose 
increase on day 8 to 800 mg/day was allowed. Assessment 
of efficacy was by the PANSS47,48 and changes in scores on 
the CGI-S and CGI-C,49 and a composite response measure 
(a PANSS total score reduction of $30% and a CGI-C score 
of 1–2). A total of 399 patients were randomly assigned, and 
six-week completion rates were 77.5% with PER, 66.7% 
with quetiapine, and 63.8% with placebo. Mean PANSS 
total change improvement was greater with PER than with 
quetiapine from day 5 through to the monotherapy endpoint 
compared with the placebo (P # 0.001). Only PER showed 
a significantly greater PANSS improvement compared with 
placebo at two weeks. Patients in the PER group showed Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
136
Gahr et al
a greater PANSS improvement than those in the placebo 
group from day 5 through to the monotherapy phase endpoint 
(P # 0.001), whereas quetiapine separated from placebo only 
at day 9. On the CGI-S and CGI-C, PER was better than both 
quetiapine (P = 0.002) and placebo (P , 0.001), whereas 
quetiapine did not separate from placebo at the two-week 
monotherapy. Significantly greater improvement with PER 
compared with quetiapine was observed at the six-week 
study endpoint, despite similar use of additive therapy. After 
six weeks, adverse event-related discontinuation rates were 
6.3% for PER, 10.1% for quetiapine, and 6.3% for placebo 
groups. The authors concluded that PER, compared with 
quetiapine, improves symptoms earlier and to a greater 
degree in patients with recently exacerbated schizophrenia 
requiring hospitalization. Remarkably, there are no published 
head-to-head-comparisons of PER and risperidone.
Patients with schizoaffective disorder
Canuso et al65 carried out a randomized, double-blind, placebo-
controlled, parallel-group study (n = 316). Eligible subjects 
were inpatients with an acute exacerbation of schizoaffective 
disorder. There was a screening period, followed by random-
ization and double-blind treatment for six weeks. During 
days 2 –5 of the screening period, all other antipsychotic medi-
cation was discontinued. Subjects were randomly assigned 
(1:1:1) to lower doses of PER (6 mg/day, with the option to 
reduce to 3 mg/day), higher doses of paliperidone (12 mg/day, 
option to reduce to 9 mg/day), or placebo. No dosage adjust-
ments were allowed after day 15. A total of 319 patients were 
randomly assigned. Changes in PANSS total scores were not 
statistically significantly different to the placebo (P = 0.187) 
at the lower doses of PER. Mean PANSS total score (primary 
outcome) improved statistically significantly with higher doses 
of PER compared with the placebo (P = 0.003).
Patients with acute mania
In a recently published study, Berwaerts et al investigated 
the efficacy of PER in the treatment of acute mania.66 They 
performed a randomized, double-blind, dose-response study 
(n = 469) and assigned subjects randomly (1:1:1:1 ratio) to 
one of three fixed doses of PER (3, 6, or 12 mg), or pla-
cebo. For inclusion, subjects were required to show a Young 
Mania Rating Scale (YMRS)67 score of $20. Mean change 
in YMRS score from baseline to the three-week endpoint 
(primary variable) was statistically significantly different 
for the PER 12 mg group (P , 0.01), but not for the 6 mg 
group (P = 0.30) or 3 mg group (P = 0.99) compared with 
placebo. Thus, the authors concluded that PER 12 mg/day 
was superior to placebo in the treatment of acute mania.66 
Additionally, change from baseline in YMRS total score 
increased with the dose of PER.
Acute mania and mixed episodes of bipolar i 
disorder
Vieta et al performed a study to investigate the efficacy of 
PER in patients with acute manic or mixed episodes of 
bipolar I disorder and secondarily to assess noninferiority 
of paliperidone versus quetiapine (as an active comparator) 
over 12 weeks of treatment.68 The study consisted of a three-
week, double-blind, acute treatment phase, during which 
patients were randomly assigned in a 2:2:1 ratio to receive 
PER 3–12 mg/day (flexibly dosed), quetiapine 400–
800 mg/day (initially titrated and flexibly dosed), or placebo. 
This phase was followed by a nine-week, double-blind 
maintenance phase, during which patients continued with 
flexible doses of their recent study medication, whereas 
patients on placebo were switched, in a blinded fashion, to 
flexibly dosed PER at an initial dose of 6 mg/day. Patients 
needed to have at least one documented manic or mixed 
episode requiring treatment within the three years prior to 
screening and a YMRS67 of $20 at screening at baseline. 
Primary efficacy variable was the change from baseline in 
YMRS total score at the three-week endpoint for PER versus 
placebo. The key secondary efficacy variable was the change 
from baseline in Global Assessment of Functioning score 
at the three-week endpoint for PER versus placebo. Other 
secondary efficacy variables included a noninferiority analy-
sis of PER and quetiapine, based on change in YMRS score 
at the 12-week endpoint. Additional endpoints were change 
in PANSS and CGI-Bipolar Disorder-Severity score (CGI-
BP-S).69 Of the 643 patients screened, 493 met the eligibility 
criteria, and were randomly assigned to the treatment groups, 
and 232 patients completed the entire 12-week study. PER 
was superior to the placebo in the reduction of YMRS scores 
at the three-week endpoint (P , 0.001) and noninferior to 
quetiapine at the 12-week endpoint. There was no significant 
difference between PER and quetiapine in onset of thera-
peutic effect, responder rate, and remission rate. A higher 
percentage of PER than quetiapine patients (13.9% versus 
7.5%, respectively) showed symptoms of depression at the 
12-week endpoint. The median mode dose during the 
12-week treatment period was 9 mg for PER and 600 mg 
for quetiapine. The authors concluded that PER was effec-
tive and tolerable in the treatment of acute mania.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Other therapeutic options
Although paliperidone is the active metabolite of risperidone 
and shares some similarities in its receptor binding profile 
with that of risperidone, it has been suggested that paliperi-
done is pharmacologically distinct from its parent 
  compound.70 Dremencov et al used animal data70 to show 
that paliperidone differentially affects serotonin and norepi-
nephrine neuronal firing compared with risperidone when 
used in combination with selective serotonin re-uptake 
inhibitors. Based on animal studies, it has been suggested 
that paliperidone may be especially useful in the treatment 
of depression in patients resistant to selective serotonin 
reuptake inhibitors.70 Corena-McLeod et al71 hypothesized 
that paliperidone could be used as a mood disorder stabilizer 
in patients with bipolar disorder. For that purpose, they 
focused on the protein profile of synaptoneurosomes isolated 
from the prefrontal cortex of the rat brain, because this 
cerebral structure has been linked to the pathophysiology 
of mood disorders. Synaptoneurosomal-enriched protein 
preparations include a collection of pre- and postsynaptic 
proteins involved in a variety of pathways, including intra-
cellular calcium signaling, energy metabolism, and neuronal 
plasticity. The authors intend to determine changes in 
expression in synaptoneurosomal-enriched prefrontal cortex 
preparations of the rat brain after chronic treatment with 
paliperidone, lithium, and valproate. Similar protein expres-
sion profiles at the synaptoneurosomal level have been 
observed, suggesting that the mode of action of paliperidone 
is similar to that of lithium and valproic acid. The expression 
profile for paliperidone is similar to that of lithium, implicat-
ing the effects of paliperidone on signaling pathways, energy 
metabolism, and synaptic plasticity. With these findings 
showing that paliperidone induces similar changes in syn-
aptoneurosomal protein expression as lithium in an animal 
model, paliperidone could act as a mood stabilizer as its 
mode of action is similar to lithium.
Critical appraisal of existing data
There is clearly some evidence that PER is more effective 
in the treatment of schizophrenic symptoms than placebo. 
However, data are primarily based on only three reason-
ably powered studies funded by the producing company. 
Head-to-head comparisons, especially with risperidone, 
have been avoided, although easily possible because some 
studies have used quetiapine or olanzapine as comparator 
substances. A number of post hoc analyses were performed 
with existing data. All assumptions made were not part of 
the original research questions. No intention-to-treat analyses 
were performed, which is a major drawback in the face of 
high dropout rates. Animal studies were used to hypothesize 
the efficacy of PER as a mood stabilizer. Without any real 
in vivo evidence, this remains pure speculation. In summary, 
there is little evidence from direct research to answer ques-
tions beyond the efficacy of PER for schizophrenia and acute 
mania. Possible data that could have given answers about the 
place of PER amongst existing treatments were not used, 
collected, or analyzed, casting some doubt on the intention 
to find out whether there is any superiority of PER compared 
with other antipsychotics justifying its significantly higher 
cost. Instead, assumptions about the efficacy of PER in many 
areas are made without direct research evidence, support 
coming merely from post hoc analyses of limited value.
Safety and tolerability
Studies that directly compared the profile of side effects of 
PER and its parent compound, risperidone, were not found. 
A study by Sun et al72 investigated the acute toxicity of PER 
and its derivatives in mice and rats. To maintain a compre-
hensive view on the safety and tolerability of PER in human 
subjects and patients, we reviewed the adverse side effects 
that occurred in the published efficacy studies of Marder 
et al, Kane et al, Davidson et al,44–46 and the symptom recur-
rence study by Kramer.61 We reviewed the pooled analysis 
of these three studies by Meltzer,53 the 52-week long-term 
pooled analysis of the aforementioned efficacy studies,52 a 
study comparing quetiapine and PER in patients with recently 
diagnosed schizophrenia,64 as well as a study on the safety and 
tolerability of PER in elderly patients with schizophrenia.59 
Table 2 displays side effects as observed in the three pivotal 
clinical trials in schizophrenia, and Table 3 shows the side 
effects of PER treatment in elderly schizophrenic patients.
In general, PER was well tolerated by patients with 
schizophrenia treated within the three six- week studies 
and the 52-week long-term study. Table 2 shows the pooled 
data on adverse side effects that occurred during the three 
six-week placebo-controlled trials. In the three six-week 
trials, serious adverse events (5%–6%) and dropouts due to 
adverse events (2%–7%) were similar in patients treated with 
PER and placebo (6% and 5%).
The pooled analysis of three long-term, open-label studies 
showed that PER was well tolerated over a 52-week treatment 
duration.52 Again, the most frequent serious adverse events 
were psychotic disorders with a rate of 5%, and depression, 
suicidal ideation, suicide attempts, and agitation, with a rate Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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of 1%.52 Treatment-emergent adverse events were observed 
in 76% of the patients treated with PER, 7% were dropouts 
due to adverse events, and two patients committed suicide 
(enrolled n = 1083, completed n = 507). Most frequently 
noted treatment-emergent adverse events were insomnia 
(14%), headache (12%), and akathisia (11%).
The study by Canuso et al,64 which compared the effi-
cacy and safety of quetiapine and PER in patients recently 
diagnosed with schizophrenia, found tremor, somnolence, 
and insomnia to be the most common adverse events during 
a two-week period, and tremor, somnolence, sedation, and 
insomnia during a six-week period. Serious adverse events 
were reported in 2.5% of patients treated with placebo, 4.4% 
of patients treated with quetiapine, and 8.2% of patients 
treated with PER.
The study by Tzimos et al59 investigating the safety and 
tolerability of PER in elderly patients with schizophrenia 
reported serious adverse events in 3% of the PER group 
(acute coronary syndrome in one patient and mania in one 
patient) and 8% of the placebo group during the double-blind 
study phase. Treatment-emergent adverse events were seen 
at similar rates in placebo (71%) and PER (67%) groups.
Acute toxicity
Sun et al72 investigated the acute toxicity of risperidone, PER, 
and its derivatives in mice and rats. They found a LD50 of 
50.89 mg/kg body weight for risperidone and 162.65 mg/kg 
for PER. The maximum tolerated dose was 5.78 mg/kg for 
risperidone and 4.11 mg/kg for PER. The maximum   tolerated 
dose was defined as the maximum drug dosage that did not 
lead to toxic manifestations or death in the experimental 
animals. Hence, PER seems to be at an advantage regarding 
lethal doses in animals, but surprisingly inferior compared 
with risperidone for tolerability.
extrapyramidal symptoms
Pooled data from three six-week efficacy studies show 
a nonlinear dose-dependent increase of extrapyramidal 
symptoms with rates of 13%, 10%, 25%, and 26% in 
patients treated with PER 3, 6, 9, and 12 mg, and 11% 
Table 2 Side effects of paliperidone extended release from pooled data of the three efficacy studies in schizophrenia*
Placebo Paliperidone ER Total
– 3 mg 6 mg 9 mg 12 mg 15 mg
(n = 355) n (%) (n = 127) n (%) (n = 235) n (%) (n = 246) n (%) (n = 242) n (%) (n = 113) n (%) (n = 963) n (%)
TEAEs in total 235 (66) 91(72) 156 ( 66) 171 (70) 184 (76) 87 (77) 689 (72)
CNS disorders
Headache 42 (12) 14 (11) 29 (12) 34 (14) 35 (14) 20 (18) 132 (14)
Akathisia 14 (4) 5 (4) 7 (3) 20 (8) 23 (10) 11 (10) 66 (7)
extrapyramidal
disorder
8 (2) 6 (5) 5 (2) 17 (7) 18 (7) 9 (8) 55 (6)
Somnolence 12 (3) 6 (5) 8 (3) 17 (7) 11 (5) 7 (6) 49 (5)
Dizziness 14 (4) 7 (6) 11 (5) 11 (4) 12 (5) 7 (6) 48 (5)
Sedation 13 (4) 1 (1) 12 (5) 8 (3) 15 (6) 2 (2) 38 (4)
Psychiatric disorders
insomnia 51 (4) 14 (11) 29 (12) 35 (14) 26 (11) 14 (12) 118 (12)
Anxiety 29 (8) 12 (9) 16 (7) 14 (6) 11 (5) 9 (8) 62 (6)
Agitation 28 (8) 7 (6) 17 (7) 13 (5) 13 (5) 3 (3) 53 (6)
Psychotic 16 (5) 5 (4) 6 (3) 7 (3) 4 (2) 4 (4) 26 (3)
Disorders
Gastrointestinal disorders
Nausea 19 (5) 8 (6) 9 (4) 10 (4) 10 (4) 2 (2) 39 (4)
vomiting 17 (5) 2 (2) 6 (3) 9 (4) 12 (5) 8 (7) 37 (4)
Constipation 20 (6) 7 (6) 8 (3) 7 (3) 7 (3) 4 (4) 33 (3)
Dyspepsia 14 (4) 3 (2) 6 (3) 5 (2) 12 (5) 6 (5) 32 (3)
Cardiac disorders
Tachycardia 10 (3) 3 (2) 17 (7) 18 (7) 18 (7) 2 (2) 58 (6)
Sinus  
tachycardia
15 (4) 11 (9) 9 (4) 10 (4) 17 (7) 8 (7) 55 (6)
QTc  
prolongation
9 (3) 4 (3) 9 (4) 7 (3) 12 (5) 4 (4) 36 (4)
Note: *Adapted from Meltzer et al.53
Abbreviations: TeAe, Treatment-emergent adverse events; eR, extended release.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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in placebo-treated patients.53 Akathisia, parkinsonism, 
dyskinesia, and dystonia were the most often reported 
extrapyramidal side effects. Only a single case of tardive 
dyskinesia was observed with PER across the studies. The 
Abnormal Involuntary Movement Scale, Barns Akathisia 
Rating scale, and   Simpson Angus Rating scale did not show 
significant median deviations across the dosage spectrum 
studied. Still, patients treated with the higher doses, ie, 
PER 9 mg and 12 mg, showed extrapyramidal symptoms 
more often.
In pooled data from the 52-week open-label studies, 
23%–25% of patients treated with PER developed extra-
pyramidal symptoms at a mean dosage of 10 mg.52 This 
was similar to patients who were treated with olanzapine or 
placebo during the six-week double-blind study phase and 
subsequently shifted to open-label PER treatment (23%–25% 
and 32%).
The study comparing quetiapine and PER64 found a higher 
incidence of extrapyramidal symptoms in the first two weeks 
on PER compared with quetiapine but not compared with 
placebo. After six weeks, there was no significant difference 
between the treatment groups with respect to extrapyramidal 
symptoms.
In elderly patients, the incidence of extrapyramidal 
symptoms was low throughout the double-blind and 
open-label study phases.59 Extrapyramidal disorders 
occurred more often in the placebo group during the 
double-blind phase, but akathisia rates were identical for 
PER and placebo at 3%. None of these events resulted in 
discontinuation.
Table 3 Safety and Tolerability in elderly Patients*
Double-blind Open-label
Placebo (n = 38) PER (n = 76) Placebo/PER (n = 30) PER/PER (n = 58)
Treatment-emergent adverse events
Overall
All TeAes 27 (71) 51 (67) 24 (80) 43 (74)
Possibly related TeAe 17 (45) 38 (50) 12 (40) 26 (45)
TeAe leading to death 2 (5) 0 0 0
Any serious TeAe 3 (8) 2 (3) 3 (7) 3 (5)
TeAe leading to discontinuation 3 (8) 5 (7) 3 (10) 3 (5)
Occurrence $ 5% in any treatment group
Nervous system disorders 9 (24) 22 (29) 8 (27) 14 (24)
extrapyramidal disorder 4 (11) 4 (5) 2 (7) 3 (5)
Somnolence 2 (5) 7 (9) 2 (7) 0
Dizziness 0 5 (7) 1 (3) 6 (10)
Headache 1 (3) 4 (5) 3 (10) 5 (9)
Cardiac disorders 5 (13) 20 (26) 8 (27) 11 (19)
Tachycardia 0 12 (16) 4 (13) 6 (10)
Psychiatric disorders 9 (24) 11 (14) 3 (10) 14 (24)
insomnia 4 (11) 7 (9) 1 (3) 9 (16)
Agitation 2 (5) 2 (3) 0 2 (3)
Anxiety 2 (5) 2 (3) 0 3 (5)
investigations 5 (13) 7 (9) 5 (17) 12 (21)
QTc prolongation 1 (3) 5 (7) 3 (10) 2 (3)
electrocardiographic T wave inversion 2 (5) 1 (1) 0 2 (3)
Gastrointestinal disorders 7 (18) 7 (9) 2 (7) 3 (5)
Nausea 2 (5) 2 (3) 0 0
vomiting 2 (5) 1 (1) 0 1 (2)
General disorders 2 (5) 5 (7) 5 (17) 10 (17)
Asthenia 2 (5) 4 (5) 4 (13) 8 (14)
Fatigue 0 1 (1) 0 3 (5)
infections and infestations 6 (16) 8 (11) 5 (17) 7 (12)
Nasopharyngitis 1 (3) 0 2 (7) 3 (5)
Pneumonia 1 (3) 1 (1) 2 (7) 0
vascular disorders 2 (5) 8 (11) 0 3 (5)
Hypertension 1 (3) 4 (5) 0 2 (3)
Hypotension 0 4 (5) 0 1 (2)
Note: *Adapted from Tzimos et al.59
Abbreviations: PeR, paliperidone extended-release; n, number of subjects; TeAe, treatment-emergent adverse events.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Metabolic effects
In the three six-week, double-blind, placebo-controlled 
studies,53 the mean increase in body weight was 0.6, 0.6, 1.0, 
1.1, and 1.9 kg on PER 3, 6, 9, 12, and 15 mg/day. Mean body 
weight change in the placebo groups was -0.4 kg and mean 
body weight increase in the olanzapine groups was 2.0 kg. 
In the 52-week extension-phase of the three six-week studies, 
the mean body weight increase in all treatment groups was 
1.1 kg, with an overall mean modal dose of PER 10 mg.52 
Compared with PER or placebo, quetiapine was associated 
with a significantly higher body weight increase of 0.8 kg 
versus 0.4/0.2 kg after two weeks and 1.1 versus 0.4/0.3 kg 
after six weeks.64 In elderly patients, there was no increase 
in mean body weight or body mass index in the active and 
placebo groups.59
Glucose metabolism was slightly affected by PER in the 
three placebo-controlled clinical trials (pooled data) with 
no significant difference between PER and placebo groups 
(rate of glucose-related adverse events was 1% each).53 This 
was confirmed in the 52-week extension, during which the 
incidence of deranged glucose metabolism was also 1% in 
patients treated with PER.52
Cardiovascular side effects
With respect to cardiovascular side effects, PER was well 
tolerated in normal-aged patients, with a slightly increased 
incidence of cardiovascular side effects among elderly 
patients.53,59 In the pooled analysis of the three six-week stud-
ies, there were no clinically relevant differences in treatment-
emergent adverse effects suggestive of a proarrhythmic 
potential between placebo or any PER treatment group. 
  Syncope was reported in a low percentage of patients receiv-
ing PER (0.8%), similar to the rate reported for placebo (1%). 
Mean QTc interval prolongation differences between patients 
treated with PER and patients treated with placebo were negli-
gible (,4 msec). There was no significant difference between 
PER and placebo regarding QTc intervals . 450 msec 
and ,480 msec. No patient treated with PER irrespective 
of dosage showed a QTc interval of $480 msec in the three 
clinical placebo-controlled trials.
In the study investigating safety and tolerability in elderly 
patients,59 there were QTc intervals $ 500 msec reported 
in two patients treated with PER during the six-week study 
phase and in one patient during the 24-week extension phase. 
All of the three patients had a history of cardiovascular dis-
ease and QTc prolongation. The study comparing quetiapine 
and PER did not verify any significant QTc prolongation in 
PER-treated or in quetiapine-treated patients.64
Prescribing information for PER regarding   prolongation 
of the QT interval contains stronger warnings than that 
for risperidone.34 The manufacturer recommends avoiding 
the concomitant use of PER with medication known to 
prolong the QTc interval, such as quinidine, amiodarone, 
sotalol, chlorpromazine, thioridazine, gatifloxazine, and 
moxifloxazine.34
endocrine side effects
The three double-blind, six-week studies found significantly 
elevated plasma prolactin levels at the six-week endpoint 
in patients treated with PER compared with baseline.53 
This increase was dose-related, with mean endpoint pro-
lactin concentrations of 130.1 ng/mL for female patients 
and 52.8 ng/mL for male patients treated with PER 15 mg 
daily (reference range 1.39–24.20 ng/mL for females, 
1.61–18.77 ng/mL for males). Mean prolactin concentration 
in the placebo groups was 20.8 ng/mL (for females) and 
12.5 ng/mL (for males). Prolactin levels remained elevated 
during the 52-week extension.52 There was no significant 
difference between PER and placebo regarding the incidence 
of probably prolactin-related adverse events in the three six-
week trials (pooled data).53 Sexual dysfunction, gynecomas-
tia, galactorrhea, amenorrhea, and menstrual dysregulation 
occurred with an incidence of 1%–2% during the 52-week 
extension. The incidence of amenorrhea and menstrual 
dysregulation increased to 4% and 5%, respectively, in the 
female study population.52
In the study investigating safety and tolerability in 
elderly patients,59 no potentially prolactin-related adverse 
events were reported for any of the patients throughout the 
double-blind phase or the open-label extension of the study. 
Nevertheless, elevated prolactin levels were reported for 
45% of the males and 49% of the females treated with PER. 
At the double-blind endpoint, median prolactin levels were 
85.3 ng/mL in females and 32.0 ng/mL in males treated 
with PER,59 ie, they were almost four-fold above the normal 
range in females and elevated by almost two-fold in males. 
It is likely that these elevations would have an effect on 
bone density.
A small study examined the relationship between risperi-
done, 9-hydroxyrisperidone (ie, paliperidone), and serum 
prolactin levels in 25 patients with psychotic disorders. The 
oral dose of risperidone correlated significantly with plasma 
concentrations of risperidone, 9-hydroxy-risperidone (the 
active moiety), and prolactin. The plasma concentration of 
9-hydroxy-risperidone, but not of risperidone, correlated 
significantly with increases in plasma prolactin. The authors Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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concluded that 9-hydroxy-risperidone may play a major role 
in causing hyperprolactinemia.73 The authors hypothesized 
that this hyperprolactinemia may be related to paliperidone’s 
lower lipophilia and longer half-life, both of which increase 
paliperidone’s ability to affect the anterior pituitary gland. As 
a result of dopamine receptor blockade, the anterior pituitary 
gland, located outside the blood–brain barrier, produces 
prolactin when stimulated.73
Berwaerts et al66 clearly showed in 37 subjects that serum 
prolactin levels on risperidone as compared with PER show 
higher peak-trough-fluctuations. Mean prolactin levels with 
risperidone were higher than with PER (mean 89.7 ± 57.4 
versus 71.8 ± 60.8 ng/mL), and that these differences dimin-
ished until day 6 (71.4 ± 61.5 versus 68.5 ± 52.6 ng/mL). The 
authors concluded that from a short-term one-week perspec-
tive, PER and risperidone result in similar prolactin levels.
It may be due to the OROS formulation that PER shows 
lower peak drug serum levels than risperidone during the 
titration phase. Furthermore, prolactin shows lower peaks 
on PER than on risperidone. Lower serum peak levels of 
the active substance, as well as of prolactin, may be the 
reason for the low incidence of prolactin-related side effects 
in spite of markedly increased prolactin levels in patients 
treated with PER.
Other reported side effects
In the literature, there are two cases with possible malignant 
neuroleptic syndrome related to treatment with PER.74,75 In 
the reported cases, possible malignant neuroleptic syndrome 
occurred at a dosage of 9 mg/day. There is also one case 
report indicating that PER is capable of inducing mania 
when administered for the treatment of paranoid schizo-
phrenia at a dosage of 9 mg/day.76 In a recently published 
case report, hepatitis occurred on treatment with clozapine 
and risperidone, and hepatic failure subsided after switch-
ing from risperidone to PER, with only a slightly reduced 
clozapine dosage.77 When used in elderly patients with psy-
chosis associated with dementia, PER, like all other atypical 
antipsychotics, has an increased risk of mortality.34 Another 
possible limitation of PER is its availability only in the OROS 
formulation that, as a consequence of its nondeformability 
and inflexibility, precludes crushing or chewing of the sub-
stance and also inhibits its application in patients suffering 
from severe gastrointestinal narrowing.
Potential for abuse and dependence
In a Medline search and a separate investigation of the 
databases of the US Food and Drug Administration and 
www.clinicaltrials.com, we could not detect any studies that 
systematically investigated the potential of PER to induce 
abuse or substance dependence. There were also no case 
reports showing PER as an agent liable to abuse or causing 
dependence. In light of this, it is not possible to give evidence 
concerning the potential of PER to be misused, abused, or 
cause tolerance or physical dependence.
Conclusion concerning adverse effects
With respect to the published literature on safety and toler-
ability so far, PER seems to be well tolerated and safe to use 
as a second-generation antipsychotic. Its primary limitations 
are prolactin elevation and extrapyramidal symptoms, both 
of which seem to be dose-related. It is noteworthy that the 
prolactin increase and incidence of potentially prolactin-
associated adverse events do not increase to the same extent. 
Weight gain increases are also verifiable, but less pro-
nounced, than with other second-generation antipsychotics 
such as olanzapine or quetiapine. PER should be prescribed 
carefully in elderly patients because of the potential for QTc 
prolongation, especially when there is a history of cardio-
vascular disease.
Patient-focused perspectives
In addition to rapid symptom control, predominantly judged 
by the physician, patient satisfaction with treatment is 
increasingly recognized as an important outcome measure. 
Recent studies suggest that patient satisfaction is an important 
measure of the effectiveness of treatment.78 Patient satisfac-
tion with antipsychotic medication plays an important role,78 
because it is positively associated with improved therapy 
adherence, improved clinical outcomes, and quality of life.79 
To our knowledge, there are no specific clinical trials focus-
ing on PER treatment and its influence on quality of life. 
There are only studies that have investigated either separate 
aspects of the “quality of life complex” or concomitantly 
assessed quality of life performance or satisfaction with 
medication within a study setting focusing on different pri-
mary outcome measures.
Canuso et al80 conducted a randomized, six-week, prospec-
tive, blinded initiation study to evaluate satisfaction with medi-
cation in patients with a suboptimal response to oral risperidone 
and switching to PER. Eligible patients were outpatients who 
continued to be symptomatic despite risperidone 4 or 6 mg/day 
for at least four weeks before randomization. Three main 
inclusion criteria had to be met, ie, score $ 4 on at least three 
specified PANSS items, reported dissatisfaction with current 
medication as measured by score # 3 (extremely to somewhat Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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dissatisfied) on item 14 (“taking all things into account, how 
satisfied or dissatisfied are you with this medication?”) of the 
Treatment Satisfaction Questionnaire for Medication,81 and, 
in the investigator’s opinion, the patient could benefit from a 
change in antipsychotic medication.
At the baseline visit, participants were randomly 
assigned in a 1:1 ratio to either immediate PER 6 mg/day 
(from day 1) or delayed initiation of PER (after two weeks 
with stable baseline dose of risperidone switching to PER 
6 mg/day on day 15) in a double-blind setting. The treatment 
period for both groups was six weeks, with possible PER 
changes in 3 mg increments starting four days after drug 
initiation. A one-item patient-reported medication satisfac-
tion questionnaire (MSQ, a patient-reported seven-point 
Likert-scale ranging from 1 (extremely dissatisfied) to 7 
(extremely satisfied) at two fixed points in time), consisting 
of the single question “Overall, how satisfied are you with 
our current antipsychotic medication(s)?” was evaluated at 
baseline and at weeks 2, 4, and 6. Item 14 of the Treatment 
Satisfaction Questionnaire for Medication was also used. 
Two hundred and one patients were screened and random-
ized, and 191 were included. In the overall population, 
the mean ± standard deviation MSQ score improved from 
2.7 ± 0.8 at baseline to 5.1 ± 1.2 at endpoint (P , 0.001). 
On the basis of dichotomized analysis of the MSQ scale, 
82.7% of participants were satisfied with their medication at 
endpoint. At the two-week time point, more participants in 
the immediate initiation group reported satisfaction (67.7%) 
compared with those in the delayed initiation group (45.3%) 
who were still receiving risperidone at this time (P = 0.002). 
Treatment Satisfaction Questionnaire for Medication score 
improved significantly at any point of time, with no signifi-
cant between-group differences at any time. The authors 
concluded that participants with schizophrenia who were 
suboptimally responsive to risperidone reported improved 
medication satisfaction after initiation of PER. It remains 
unclear why PANSS score changes were not used as an 
outcome measure. This is, however, in keeping with the 
industry’s reluctance to fund head-to-head studies in these 
circumstances.
In the study by Kramer et al,61 the primary efficacy 
variable was symptom recurrence under treatment with 
PER after an acute exacerbation of the disease. Secondary 
efficacy measures also included quality of life, assessed by 
the Schizophrenia Quality of Life Scale.60 However, the 
authors only mentioned significant improvements in scores 
on this instrument compared with placebo without   presenting 
detailed results.
The study of Tzimos et al59 primarily investigated the 
safety and tolerability of PER in elderly patients. They 
also performed an assessment of quality of life using the 
Schizophrenia Quality of Life Scale60 as a secondary efficacy 
measure. Although no formal statistical analysis was con-
ducted, the authors reported no detected differences between 
the two groups (active versus placebo) as measured by the 
Schizophrenia Quality of Life Scale scores.
Canuso et al64 performed a study to compare the short-
term efficacy and safety of PER versus quetiapine in patients 
with recently exacerbated schizophrenia. Participants were 
administered the MSQ.82 Mean changes in the scores of this 
instrument showed a nonsignificant trend in the direction of 
more treatment satisfaction in the group treated with PER as 
compared with quetiapine or placebo, whereas mean changes 
with quetiapine and placebo were comparable.
Conclusion
This is the first independent review of PER. We aimed to 
determine its place in modern antipsychotic therapy and tried 
to compare PER with its precursor, risperidone, in view of 
mounting concerns about its cost-effectiveness. PER was 
first approved for the treatment of schizophrenia in 2006 in 
the US. The three short-term, randomized, double-blind, 
placebo-controlled clinical trials conducted so far have 
documented that PER 3–15 mg/day appears to be efficacious, 
safe, and well tolerated in adult patients with schizophrenia. 
Long-term data confirmed the findings of the short-term 
trials and indicated low liability to cause metabolic effects, 
such as weight gain, hyperglycemia, and lipid dysregulation. 
Effects on prolactin are substantial. The efficacy and toler-
ability of PER in the treatment of schizoaffective disorder 
and acute manic episodes has also been demonstrated in the 
clinical trials.
At this time, there are no published data for randomized 
controlled head-to-head comparisons of PER with risperi-
done, and we found no data examining the utility of PER 
in patients previously intolerant to risperidone or for whom 
risperidone was ineffective. Therefore, a final answer to the 
important question “Is PER worth the extra cost?” is not 
possible at the moment. As a consequence, and given that 
there are no ongoing head-to-head trials comparing PER with 
risperidone (according to www.clinicaltrials.com), there is 
a definite need for at least further indirect comparisons of 
the substances. Taking into account the high percentage of 
author groups with a direct affiliation to the manufacturer of 
PER (especially when regarding review articles dealing with 
PER) further studies should be performed by independent Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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  researchers. It is impossible to conclude from the currently 
available data that PER is superior to risperidone. It does, 
however, confer certain advantages for a limited group 
of patients who cannot continue successful risperidone 
therapy.
Our main findings can be summarized as follows:
•	 PER appears to be an efficacious and well tolerated 
treatment for schizophrenia and schizoaffective disorder, 
reflecting its approval status
•	 Existing evidence on PER originates from a limited number 
of studies that meet high methodological requirements
•	 Our review revealed a striking lack of published head-to-
head comparisons of PER with its mother substance and 
predecessor risperidone, although they were both first 
introduced to the market by the same manufacturer
•	 PER differs from risperidone in a number of its pharma-
cological properties
•	 In the absence of direct and naturalistic PER versus ris-
peridone studies we cannot decide whether the substan-
tially higher daily drug costs of PER are counterbalanced 
by clear advantages over risperidone in terms of efficacy 
or tolerability.
Role in modern pharmacotherapy
It is clear that PER and its mother substance, risperidone, 
are by no means identical in terms of pharmacology. In other 
words, risperidone and its active metabolite 9-hydroxy-
risperidone, particularly when combined with the OROS 
technology, can be considered to be two distinct antipsychot-
ics. PER offers some obvious advantages in pharmacokinetic 
properties compared with risperidone. From a pharmacologi-
cal perspective, PER differs from all available antipsychotics. 
This clearly leaves room for PER in the still limited arsenal 
of so-called second-generation antipsychotics.
With regard to pharmacokinetic and pharmacodynamic 
properties, PER offers several meaningful advantages. 
Taking into account the high proportion of patients with 
schizophrenia who have comorbid hepatic impairment,83 the 
predominantly renal elimination of paliperidone appears to 
be an advantage (eg, in cases where amisulpride is not an 
option). Negligible hepatic metabolism is one of the two 
main differences between PER and its parent compound 
risperidone. At least theoretically, it is also less prone to 
pharmacogenetic effects associated with CYP 2D6 ultrarapid 
or poor metabolizer status. Compared with risperidone, PER 
has a lower risk of causing hepatic drug–drug-interactions, 
particularly in multimorbid patients with polypharmacy. 
The possibility of obtaining smooth drug plasma levels using 
the OROS system accompanied by a once-daily formulation 
and no need for dose titration is the second specific property 
of PER. These improved pharmacological properties should 
enlarge the population of patients that can benefit from 
antipsychotic therapy with PER, and might improve symp-
tom control and compliance in patients who have already 
responded positively to risperidone.
Because the shell of PER is nonabsorbable, it will appear 
in feces and possibly cause concern in patients with acute or 
paranoid psychopathology. Detailed patient information about 
this aspect, should given routinely, although this method of 
excretion could limit the use of PER in some patient groups.
We conclude that PER offers distinct and specific benefits 
resulting from its pharmacokinetic profile. This renders it 
potentially useful in a limited group of patients who have 
responded to risperidone but are unable to continue with 
risperidone treatment for a variety of reasons:
•	 Its primarily renal metabolism makes PER a treatment 
of choice in those with hepatic impairment who have 
previously responded to risperidone
•	 Its long half-life makes PER a treatment of choice in those 
with limited compliance who have previously responded to 
risperidone but cannot be persuaded to accept a intramus-
cular depot medication with risperidone microspheres
•	 Its relatively favorable extrapyramidal side effect 
profile makes PER a treatment of choice in those who 
have responded to risperidone but could not tolerate its 
extrapyramidal side effects.
Despite theoretically convincing benefits for selected 
patients, financial costs seem to be the limiting factor in 
administering PER. The commissioners of health care criti-
cize PER as a pseudoinnovation without added advantages 
over its mother substance. This position cannot be justified in 
light of the data presented here. One may want to criticize the 
price policy of the manufacturer as well as the very restrictive 
position of health care commissioners, but the relationship 
between additional costs and actual therapeutic advantage 
over risperidone is a crucial and legitimate point. Similar 
problems have arisen with the use of escitalopram (versus 
citalopram) and valproate semisodium (versus valproate 
chrono). The price policy of Janssen-Cilag led to a refusal of 
drug cost reimbursement higher than that of risperidone by 
health care providers (Table 4 shows a comparison of costs of 
daily drug doses in Germany between PER and risperidone). 
This led to de facto withdrawal of the drug in Germany, 
because the majority of patients who could potentially benefit 
from the special characteristics of the drug are not able to 
pay the daily costs of PER themselves.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Pharmacoeconomic considerations are one of the main 
factors in the course of deciding whether PER offers an overall 
improvement in antipsychotic treatment compared with other 
agents, especially risperidone. Three cost-effectiveness analy-
ses have shown PER to yield better outcomes and lower costs 
than alternative antipsychotics in patients with schizophrenia 
in Greece,84 the US85 (with estimated annual cost savings 
of US$793 in favor of PER as compared with oral risperi-
done), and Italy.86 An important limitation of the results of 
these studies is that the pharmacoeconomic models were not 
based on the results of head-to-head-trials, thus precluding 
accurate conclusions. With the availability of oral risperidone 
as a generic medication, the cost of oral PER will become 
a significant obstacle to its therapeutic use. In Germany, for 
example, the public health system terminated the financial 
support for PER in November 2009, resulting in additional 
costs for patients who stand to benefit from treatment with this 
antipsychotic. In the UK, many regional health care providers 
have limited PER to named patient use only.
Therefore, the treatment situation needs to be critically ana-
lyzed in order to balance increased financial contribution with 
the advantages of PER. We also have to acknowledge that PER 
was not part of any of the major meta-analyses that compared 
first-generation and second-generation antipsychotics. This 
further renders a final judgment on the PER’s position among 
the other antipsychotics difficult. In short, existing evidence 
cautiously suggests a place for PER in modern antipsychotic 
therapy in terms of its unique pharmacology, irrespective of 
what future pharmacoeconomic studies will yield. Patients 
who may benefit from PER are limited to those who have 
responded to risperidone in the past, but are unable to continue 
on it because of compliance issues, extrapyramidal side effects, 
or hepatic impairment.
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